RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer
RenovoRx (Nasdaq: RNXT) announced a peer-reviewed publication in Case Reports in Oncology. The study, led by researchers at Hackensack Meridian Health, showed promising results for two locally advanced pancreatic cancer patients treated with the company's TAMP platform and RenovoCath device. The patients experienced tumor responses and reductions in CA 19-9 markers.
How this was made
The 30-second read
Why it matters
The case series provides the first peer‑reviewed clinical evidence supporting the platform, which could influence valuation and partnership interest.
Market read
New clinical data may lift RNXT shares and affect the broader targeted oncology device market.
What to watch
Small sample size and lack of control group limit the robustness of the findings.
Background
RenovoRx (NASDAQ: RNXT) develops the Trans‑Arterial Micro‑Perfusion (TAMP) platform and the RenovoCath device for localized drug delivery.
Ticker impact
RenovoRx announced a peer‑reviewed case series showing tumor response and CA 19‑9 reductions using its FDA‑cleared RenovoCath TAMP platform in locally advanced pancreatic cancer.
likely upward pressure as investors price in the supportive data.
First disclosure of clinical case results; data are favorable and may improve market perception of the device and pipeline.
Market effects
Strengthens the targeted drug‑delivery device sector and may boost comparable oncology device companies.
Potentially positive for US biotech and medical‑device investors.
Adds to global interest in intra‑arterial chemotherapy approaches.
Counterpoint
Early case series may not translate to larger trials; investors should watch for Phase III results before committing.
Key entities
- companyRenovoRx, Inc.
US‑listed biotech developing the TAMP platform.
- institutionHackensack Meridian Health Jersey Shore University Medical Center
Site where the case series was conducted.
